Approach to alternative to animal experiments

Approach to alternative to animal experiments

At Mandom, based on the principles of animal welfare and the 3Rs* (especially "Replacement"), since 2005 we have been working to strengthen our internal system to develop replacements for animal experiments using three approaches. We will continue to work in this direction to meet the expectations of society.

Reference: The Japanese Society for Alternatives to Animal Experiments

* 3Rs:
   Replacement (Using other methods that do not involve animals)
   Reduction (Decrease the amount of use of animals)
   Refinement (Lessen the suffering caused to animals)

Approach to alternative to animal experiments

Mandom International Research Grants on Alternative to Animal Experiments

  1. Mandom has been providing grants for research on alternatives to animal experiments since 2008. See below for more details.

Mandom International Research Grants on Alternative to Animal Experiments.
(List of research themes)

  Name Affiliation Research theme
10th
(2017)
Shinji Sugiura Biotechnology Research Institute for Drug Discovery, National Institute of Advanced Industrial Science and Technology (AIST) Development of pressure driven multi-throughput organs-on-a-chip platform.
Kenji Usui Faculty of Frontiers of Innovative Research in Science and Technology (FIRST), Konan University Development of easy-to-use skin sensitization test for poorly water-soluble substances using peptidyl beads.
9th
(2016)
Yuji Yoshiyama Kitasato University Effects of hydrogen gas on H9c2 cardiomyocytes from ischemia reperfusion injury.
Kousei Ito Chiba University Establishment of in vitro cell assay system of drug-induced liver injury risk compounds related to mitochondrial toxicity.
8th
(2015)
Kouichi Yoshinari Department of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka Development of the prediction method for repeated dose toxicity of chemical compounds based on the statistical data analysis using in vivo toxicity database and in vitro assays.
Seiichi Ishida National Institute of Health Sciences, Division of Pharmacology Development of in vitro culture system mimicking human liver functionality by the co-culture of HepaRG, human hepatocyte progenitor cell line, and liverstellate cells.
7th
(2014)
Toshihiro Ona Kyushu University Development of universal method in skin stimulus measurement using epidermal keratinocyte mitochondria as a forefront of sensory system for homeostasis maintenance.
Takashi Yoshikado
Yuichi Sugiyama
Sugiyama Laboratory, RIKEN Innovation Center, RIKEN Prediction of the risk of drug-induced cholestasis based on the functional evaluation of bile canalicular transporters in vitro.
6th
(2013)
Satoru Koyanagi Graduate School of Pharmaceutical Sciences, Kyushu University Establishment of in vitro circadian clock system for evaluation of cell protecting mechanism against oncogenic transformation.
5th
(2012)
Hisamitsu Hayashi Graduate School of Pharmaceutical Sciences, The University of Tokyo Search for new candidate drugs for Progressive Familial Intrahepatic Cholestasis Type 2 (PFIC2).
Hirokazu Kaji Graduate School of Engineering, Tohoku University Development of a cell-based model of the retina within a microfluidic device.
4th
(2011)
Jeong Ik Lee Konkuk University Development of biomimetic tissues from commercial cell lines:
The promising alternative tools for laboratory animals.
Hideto Ariumi Kitasato University Acetylcholine inhibits the hypoxia and hydrogen peroxide -induced reduction of connexin43 protein in rat cardiomyocytes.
Naoki Yamamoto Fujita Health University A study of the eye irritation test using new immortalized human corneal epithelium.
3rd
(2010)
Hiroyuki Kusuhara Graduate School of Pharmaceutical Sciences, The University of Tokyo Establishment of quantitative prediction of in vivo renal clearance based on in vitro data obtained using human derived materials and overexpression systems.
Masahiro Takagi Japan Advanced Institute of Science and Technology Development of an Alternative method to Draize Test by Analysis of Biomimetic Membrane Dynamics.
2nd
(2009)
Kikuo Komori Graduate School of Pharmaceutical Sciences, The University of Tokyo Formation and Functional Evaluation of a Minimum Cell Mass for In Vitro Toxicity Tests.
Shigehiro Ohdo Graduate School of Pharmaceutical Sciences, Kyushu University Establishment of chronopharmacokinetic evaluation system in vitro cultured cells:
Molecular basis for rhythmic expression of CYP in serum-shocked HepG2 cells.
Kazuya Maeda Graduate School of Pharmaceutical Sciences, The University of Tokyo Establishment of the methods for quantitative prediction of the detoxification activity of drugs and the risk of drug-drug interactions in the liver by the use of human liver samples and gene expression systems.
- Use of human-derived organ samples as alternatives of animal experiments -
1st
(2008)
Kenji Sugibayashi Josai University Permeation of several compounds through different three-dimensional cultured human skin models.
Tsutomu Kurosawa Osaka University Establishment of the alternative method of animal experiment, using green fluorescent ES and iPS cells.
Jae Hak Park Seoul National University International Validation of Bovine Corneal Opacity and Permeability (BCOP) assay and introduction of "MCTT Skin model" as an alternative to skin irritation test.
Jeong Ik Lee Tokai University Study on the hazardous effects of intra-peritoneal injection of anesthetics on internal organs.
-Resolution on the mechanism of the direct hazard of anesthetic injection on cell lines derived from the liver cells and pancreatic islet cells in vitro-

Our Position on Animal Experiments

Mandom is working to develop cosmetics based
on a policy of no animal Experiments.

Mandom develops products with the safety of the consumer as our top priority. Fundamentally, the safety testing of our products is to be done on people (patch tests, stinging tests, etc.) and by using alternatives to animal Experiments. No animal Experiments is to be performed, which includes outsourcing. No animal testing will remain our policy in the future.

We are grateful for the valuable opinions expressed by our stakeholders, and will reflect them in product development that is both safe and eco-friendly.